{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"48"}],"units":"Participants"}],"description":"Percent of Particpants Achieving Overall combined complete response (CR w/normalized serum κ:λ ratio + CR + near complete response (nCR)) following induction therapy.\n\n* CR criteria: negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow.\n* κ:λ ratio: normal free light chain (FLC) ratio\n* nCR criteria: positive immunofixation analysis of serum or urine as the only evidence of disease; disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow.","groups":[{"description":"bortezomib, dexamethasone, and thalidomide","id":"OG000","title":"Three Drug Regimen (VDT)"},{"description":"bortezomib, dexamethasone, thalidomide, and cyclophosphamide","id":"OG001","title":"Four Drug Regimen (VDTC)"}],"paramType":"NUMBER","populationDescription":"The response-evaluable population is defined as all subjects who have measurable disease at baseline, receive at least 1 dose of any study drug and have at least 1 post-baseline response assessment. The response-evaluable population comprises 49 subjects in the VDT treatment group and 48 subjects in the VDTC group.","reportingStatus":"POSTED","timeFrame":"all data included in clinical database as of 10 April 2009","title":"Percent of Particpants Achieving Overall Combined Complete Response (CR) Following Induction","type":"PRIMARY","unitOfMeasure":"percentage of participants"}